|
|
Maternal mediators of fetal growth restriction linked to prenatal alcohol exposure |
| 1R01AA029594-01A1 |
|
NIAAA |
2022 |
|
|
Cardiovascular disease in fetal alcohol spectrum disorder |
| 1U01AA030185-01 |
|
NIAAA |
2022 |
|
|
Project 2: Prenatal Alcohol Exposure (PAE) and Fetal Alcohol Spectrum Disorder (FASD) |
| 1U54AA030451-01 |
|
NIAAA |
2022 |
|
|
Prenatal Alcohol Exposure and Fetal Alcohol Spectrum Disorder |
| 1U54AA030463-01 |
|
NIAAA |
2022 |
|
|
Prenatal Alcohol and Neuroimmunity |
| 5R01AA022460-08 |
|
NIAAA |
2022 |
|
|
Fetal alcohol exposure: effects on immunity of the premature newborn |
| 5R01AA027020-04 |
|
NIAAA |
2022 |
|
|
Implementing genomic medicine in clinical care of deaf patients |
| 3R01DC012115-09S1 |
|
NIDCD |
2022 |
|
|
Neurocognitive Approaches to Communication Disorders |
| 3T32DC007361-15S1 |
|
NIDCD |
2022 |
|
|
Spiral Ganglion Health: from Genomics to Gene Therapy |
| 5K08DC019716-02 |
|
NIDCD |
2022 |
|
|
Auditory Processing of Complex Sounds |
| 5R01DC001641-31 |
|
NIDCD |
2022 |